About SensID
SensID is a company based in Rostock (Germany) founded in 2015 by Bjorn Nowack was acquired by Microbiologics in November 2024.. SensID offers products and services including gDNA Reference Standards, cfDNA / ctDNA, Plasma Reference Standards, and FFPE Reference Standards. SensID operates in a competitive market with competitors including InDex Pharmaceuticals, C3J Therapeutics, Genedrive, Combinati and Qantgene, among others.
- Headquarter Rostock, Germany
- Founders Bjorn Nowack
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sensid Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
Microbiologics
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Microbiologics
(Nov 06, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SensID
SensID offers a comprehensive portfolio of products and services, including gDNA Reference Standards, cfDNA / ctDNA, Plasma Reference Standards, and FFPE Reference Standards. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Standards for genomic DNA analysis in diagnostics
Reference materials for circulating tumor DNA testing
Controls for liquid biopsy and DNA-free applications
Standards for tissue-based genomic analysis
Funding Insights of SensID
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2018 | Amount | Series A - SensID | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SensID
SensID has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Microbiologics and GENIUS Venture Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to technology startups in Mecklenburg-Vorpommern.
|
Founded Year | Domain | Location | |
|
Lyophilized quality control microorganisms are supplied for diverse industries.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SensID
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SensID
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sensid Comparisons
Competitors of SensID
SensID operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as InDex Pharmaceuticals, C3J Therapeutics, Genedrive, Combinati and Qantgene, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| domain | founded_year | HQ Location |
Pathogen-specific antimicrobials are developed for microbial dysbiosis diseases.
|
|
| domain | founded_year | HQ Location |
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis
|
|
| domain | founded_year | HQ Location |
Integrated digital PCR platform with microfluidic consumables is developed.
|
|
| domain | founded_year | HQ Location |
Cancer screening blood tests are offered for early disease detection.
|
|
| domain | founded_year | HQ Location |
PCR-based Human and Animal testing for vector-borne diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sensid
Frequently Asked Questions about SensID
When was SensID founded?
SensID was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is SensID located?
SensID is headquartered in Rostock, Germany. It is registered at Rostock, Mecklenburg-vorpommern, Germany.
What does SensID do?
SensID was founded in 2015 in Rostock, Germany, within the biotechnology sector. Reference materials, including tissue blocks and slides, are provided for DNA diagnostic uses such as RD, instrument validation, external controls, and quality control of diagnostic kits. These materials incorporate genetic modifications like point mutations, insertions, deletions, amplifications, and translocations in gDNA, cfDNA, and ctDNA. Compatibility is ensured with assays including FISH, immunohistochemistry, PCR, sequencing, and FACS.
Who are the top competitors of SensID?
SensID's top competitors include C3J Therapeutics, InDex Pharmaceuticals and Genedrive.
What products or services does SensID offer?
SensID offers gDNA Reference Standards, cfDNA / ctDNA, Plasma Reference Standards, and FFPE Reference Standards.
Who are SensID's investors?
SensID has 2 investors. Key investors include Microbiologics, and GENIUS Venture Capital.